Cross-Sector entity
Of the tracked stories, 3 of 3 also mention Assure system, the most common co-covered peer. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. The tracked stories average 2 original sources each.
3 verified stories tracked
Last mentioned: Mar 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 3 of 3 also mention Assure system, the most common co-covered peer. earnings accounts for 1 of the 3 tracked stories, while 2 other categories carry the remainder. The tracked stories average 2 original sources each. Kestra Medical appears in 3 tracked Cross-Sector stories from March 18, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kestra Medical. Shared-story counts are live from our verified record — not editorial picks.
Expansion Target
Goal to reach 130 active sales territories by fiscal year-end
Earnings Release
Announced 63% revenue growth and VA hospital network access
Q3 Fiscal End
Closed third quarter with 100 active sales territories
Equity Offering
Completed capital raise to bolster cash position to $291M
Kestra Medical (KMTS) delivered a strong Q3 2026 performance, highlighted by a 63% year-over-year revenue increase and the ninth consecutive quarter of gross margin expansion. While net losses widened to $34.2 million due to aggressive sales force expansion, the company secured critical access to the VA Federal Supply Schedule and expanded its Florida Medicaid footprint.
Kestra Medical reported a 63% year-over-year revenue increase to $24.6 million in Q3 2026, driven by record prescriptions for its Assure wearable cardioverter defibrillator. The company significantly expanded its market access through a new U.S. Department of Veterans Affairs contract and improved Medicaid coverage in Florida.
Kestra Medical (KMTS) delivered a robust Q3 2026 with $24.6 million in revenue, driven by a 58% surge in Assure system prescriptions. Despite a widening net loss of $34.2 million, the company secured critical access to the VA Federal Supply Schedule and expanded its Florida Medicaid footprint.
Source: fool.com · Motley Fool Transcribing (us)
